Trial of AEB071 in Combination With BYL719 in Patients With Melanoma

Learn more about:
Related Clinical Trial
A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma Managed Access Program Supporting Patient Access to Tebentafusp Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Early Integration of Supportive Care Into Standard Oncology Care for Metastatic Uveal Melanoma Patients Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma A Prospective Natural History Study in Uveal Melanoma Uveal Melanoma and Brachytheraphy: Long-term Outcomes. A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation and Randomized, Masked Dose Expansion Designed to Evaluate Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery A Study of PLX2853 in Advanced Malignancies. Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) Treatment Of Radiation Retinopathy Trial Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Study in Subjects With Small Primary Choroidal Melanoma Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Trial of AEB071 in Combination With BYL719 in Patients With Melanoma Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Pembrolizumab in Treating Patients With Advanced Uveal Melanoma Vascular Response to Brachytherapy Using Functional OCT Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma New Biopsy Technique for Uveal Melanoma Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy Intermittent Selumetinib for Uveal Melanoma Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma Vorinostat in Patients With Class 2 High Risk Uveal Melanoma Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases A Phase II Study of BVD-523 in Metastatic Uveal Melanoma Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma Treatment With Intravitreal Avastin for Large Uveal Melanomas

Brief Title

Trial of AEB071 in Combination With BYL719 in Patients With Melanoma

Official Title

Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination With BYL719, a PI3Kα Inhibitor, in Patients With Metastatic Uveal Melanoma

Brief Summary

      Primary objective is to define the maximum tolerated dose (MTD) for the combination of AEB071
      and BYL719. Secondary objectives are to define the safety and tolerability of AEB071 and
      BYL719.
    

Detailed Description

      Uveal melanoma is the most common primary intraocular malignancy in adults and is thought to
      be particularly resistant to systemic treatment, and no systemic therapy has yet been
      demonstrated to improve survival. Drugs commonly used to treat advanced cutaneous melanoma
      rarely achieve durable responses in patients with uveal melanoma. Because of the lack of
      effective systemic treatment options, outcomes are poor once metastatic disease occurs, and
      the median survival from the time of the development of distant metastatic disease is 6 to 12
      months. Although it is clear that novel effective therapies are desperately needed for this
      disease, the development of such therapies has been hampered by the rarity of uveal melanoma.
    

Study Phase

Phase 1

Study Type

Interventional


Primary Outcome

Total maximum tolerated dose (in milligrams) of AEB071 in combination with BYL719

Secondary Outcome

 Number of participants with adverse events

Condition

Uveal Melanoma

Intervention

AEB071

Study Arms / Comparison Groups

 AEB071 and BYL719
Description:  AEB071, oral, 100-400 mg twice daily BYL719, oral, 200-350 mg daily

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

30

Start Date

November 2014

Completion Date

December 2018

Primary Completion Date

March 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Metastatic histologically or cytologically confirmed uveal melanoma with pathologic
             confirmation at a participating center that is judged to be progressive in the opinion
             of the treating physician.

          -  Measurable disease. Patients with biopsy-proven metastatic disease that do not meet
             criteria for measurable disease may be eligible at the discretion of the principal
             investigator.

          -  Prior cytotoxic therapy and immunotherapy are allowed. For the dose escalation, prior
             targeted therapy with a MEK inhibitor, Protein Kinase C inhibitor, Akt, or mechanistic
             target of rapamycin (mTOR) inhibitor are allowed. For the dose expansion cohort, no
             prior PKC, Akt, or mTOR inhibitors are allowed. Local therapies such as radiofrequency
             ablation or cryotherapy for metastatic disease are permitted but must have been
             performed at least 21 days prior to initiation of study therapy.

          -  Age greater than or equal to 18 years

          -  Willingness to undergo core biopsies at baseline, mid-Cycle 1, and/or at progression
             unless contraindicated by medical risk in the opinion of the treating physician.

          -  Easter Cooperative Oncology Group (ECOG) performance status less than or equal to 2
             (Karnofsky greater than or equal to 60 percent).

          -  Life expectancy of greater than 3 months.

          -  Able to swallow and retain medication and does not have any clinically significant
             gastrointestinal abnormalities that may alter absorption such as malabsorption
             syndrome or major resection of the stomach or bowels.

          -  Fasting plasma glucose (FPG) less than 140 mg/dL / 7.8 mmol/L.

          -  All prior treatment-related toxicities must be grade less than or equal to 1 (except
             alopecia).

          -  Patients must have adequate organ and marrow function within 14 days of starting Cycle
             1, Day 1 of therapy

          -  Women of child-bearing potential and men must agree to use adequate contraception
             prior to study entry and for the duration of study participation. Women of
             child-bearing potential must have a negative serum pregnancy test within 14 days prior
             to registration.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  History of another malignancy except for those who have been disease-free for 24
             months. Patients with a history of completely resected non-melanoma skin cancer and/or
             patients with indolent secondary malignancies not requiring active therapy are
             eligible.

          -  Any major surgery or extensive radiotherapy within 28 days prior to screening

          -  Use of other investigational drugs within 28 days (or five half-lives, whichever is
             longer) preceding the first dose of AEB071 and BYL719.

          -  Symptomatic or untreated leptomeningeal or brain metastases or spinal cord
             compression. Treated brain metastases must have been stable for at least 1 month.

          -  Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to AEB071 or BYL719.

          -  Current use of a prohibited medication.

          -  Type I Diabetes Mellitus (DM), Type II DM patients requiring insulin for chronic blood
             glucose control, and any patients with a fasting blood glucose greater than 140 mg/dL
             at screening.

          -  History or evidence of cardiovascular risk.

          -  Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C
             Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection,
             which will be allowed).

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection and psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Patients with impairment of gastrointestinal function or gastrointestinal disease that
             could interfere with the absorption of AEB071 or BYL719 (e.g. ulcerative disease,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel
             resection).

          -  Patients who have received prior systemic anti-cancer treatment, such as cyclical
             chemotherapy or biological therapy within a period of time that is shorter than the
             cycle length used for that treatment (e.g. 6 weeks for nitrosourea, mitomycin-C) prior
             to starting study treatment.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Richard Carvajal, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT02273219

Organization ID

AAAN4901

Secondary IDs

CAEB071AUS01T

Responsible Party

Sponsor-Investigator

Study Sponsor

Richard D. Carvajal


Study Sponsor

Richard Carvajal, MD, Principal Investigator, Columbia University


Verification Date

June 2018